➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Baxter
McKinsey
Johnson and Johnson
Harvard Business School

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

Patent: 6,861,243

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,861,243
Title: Genes containing a DNA sequence coding for hydroxynitrile lyase, recombinant proteins derived therefrom and having hydroxynitrile lyase activity, and use thereof
Abstract:New genes containing a DNA sequence coding for hydroxynitrile lyase, which genes can be prepared via a primer combination based on the DNA sequence of the 5\'-region of the mdl genes from Prunus serotina and from Prunus amygdalus and/or a primer 2 based on the 3\'-region of the DNA sequences of one of the hydroxynitrile lyase isoenzymes from Prunus serotina or from Prunus amygdalus, subsequent amplification with a DNA polymerase using a DNA from organisms, containing genes coding for hydroxynitrile lyase, as templates and cloning, and also recombinant proteins which can be prepared in suitable host cells by heterologous expression of the DNA sequence of said HNL genes, and proteins and fusion proteins derived therefrom and use of said proteins for preparing (R)- or (S)-cyanohydrins.
Inventor(s): Schwab; Helmut (Graz, AT), Glieder; Anton (Gleisdorf, AT), Kratky; Christoph (Graz, AT), Dreveny; Ingrid (Graz, AT), Pochlauer; Peter (Linz, AT), Skranc; Wolfgang (Vienna, AT), Mayrhofer; Herbert (Engerwitzdorf, AT), Wirth; Irma (Enns, AT), Neuhofer; Rudolf (Engerwitzdorf, AT), Bona; Rodolfo (Graz, AT)
Assignee: DSM Fine Chemicals Austria NFG GmbH & Co. KG (Linz, AT)
Application Number:10/046,232
Patent Claims:see list of patent claims

Details for Patent 6,861,243

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial DSM Fine Chemicals Austria NFG GmbH & Co. KG (Linz, AT) 2021-01-16 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial DSM Fine Chemicals Austria NFG GmbH & Co. KG (Linz, AT) 2021-01-16 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial DSM Fine Chemicals Austria NFG GmbH & Co. KG (Linz, AT) 2021-01-16 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Johnson and Johnson
Baxter
McKesson
Merck
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.